| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 07/29/2010 | WO2010085358A2 Flaviviruses expressing the prm, e, and ns1 proteins of other flaviviruses and uses thereof |
| 07/29/2010 | WO2010085262A1 In vivo and ex vivo gene transfer into renal tissue using gutless adenovirus vectors |
| 07/29/2010 | WO2010085162A2 Expression cassettes, T-DNA molecules, plant expression vectors, transgenic plant cells as well as the use thereof in the production of a vaccine |
| 07/29/2010 | WO2010084999A1 Immunosuppressive agents and prophylactic and therapeutic agents for autoimmune diseases |
| 07/29/2010 | WO2010084408A2 Pta089 protein |
| 07/29/2010 | WO2010084350A1 Mutant pathogenic bacterial and live attenuated vaccine compositions |
| 07/29/2010 | WO2010084324A1 Ljungan virus with improved replication characteristics |
| 07/29/2010 | WO2010084298A1 Stable vaccine compositions and methods of use |
| 07/29/2010 | WO2010084197A1 Methods for producing mixtures of antibodies |
| 07/29/2010 | WO2010084158A1 Anti-cd 160 monoclonal antibodies and uses thereof |
| 07/29/2010 | WO2010083728A1 Nanoparticle formulated glycolipid antigens for immunotherapy |
| 07/29/2010 | WO2010083581A1 Method for preparing an immunostimulant from a brucella lysate, and product |
| 07/29/2010 | WO2010065079A3 Antibodies to il-6 and use thereof |
| 07/29/2010 | WO2010064208A3 Msp2 antigenic peptides and their use |
| 07/29/2010 | WO2010064012A3 Treatment of autoimmune disease by modulating annexin-i (lipocortin 1 ) |
| 07/29/2010 | WO2010042919A3 Method of making a vaccine |
| 07/29/2010 | WO2010041140A3 Treatment of proliferative disorders with a death receptor agonist |
| 07/29/2010 | WO2010033275A3 Orally administerable vaccine for yersinia pestis |
| 07/29/2010 | WO2010010466A3 Neutralizing anti-influenza a virus antibodies and uses thereof |
| 07/29/2010 | WO2009076158A8 Compositions for inducing immune responses |
| 07/29/2010 | WO2007048089A3 Multi-plasmid system for the production of influenza virus |
| 07/29/2010 | US20100191325 Coating containing pegylated hyaluronic acid and a pegylated non-hyaluronic acid polymer |
| 07/29/2010 | US20100190964 Antibodies to human ErbB4 |
| 07/29/2010 | US20100190962 Novel serpentine transmembrane antigens expressed in human cancers and uses thereof |
| 07/29/2010 | US20100190838 Connective Tissue Growth Factor Fragments and Methods and Uses Thereof |
| 07/29/2010 | US20100190232 Functional Mutations In Respiratory Syncytial Virus |
| 07/29/2010 | US20100189775 Pharmaceutical composition and pharmaceutical kit for the treatment of hepatocellular carcinoma |
| 07/29/2010 | US20100189773 5-cyano-4- (pyrrolo [2,3] pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors |
| 07/29/2010 | US20100189772 Compositions of TLR ligands and antivirals |
| 07/29/2010 | US20100189769 Polypeptide Films and Methods |
| 07/29/2010 | US20100189764 Bioactive mesh |
| 07/29/2010 | US20100189757 Drug depot implant designs and methods of implantation |
| 07/29/2010 | US20100189750 Methods of treating tumors in immune-privileged sites |
| 07/29/2010 | US20100189749 Methods for producing yeast-based vaccines |
| 07/29/2010 | US20100189748 Inactivated staphylococcal whole-cell vaccine |
| 07/29/2010 | US20100189747 Compositions and methods for treating or preventing hiv infection |
| 07/29/2010 | US20100189746 Adaptation of pitman moore strain of rabies virus to primary chick embryo fibroblast cell cultures |
| 07/29/2010 | US20100189745 Production of Viral Vaccine |
| 07/29/2010 | US20100189744 Papillomavirus vaccine compositions |
| 07/29/2010 | US20100189743 Circovirus sequences associated with piglet weight loss disease (pwd) |
| 07/29/2010 | US20100189742 HPV epitopes targeted by T cells infiltrating cervical malignancies for use in vaccines |
| 07/29/2010 | US20100189741 Oil-in-water emulsion influenza vaccine |
| 07/29/2010 | US20100189740 Modified polysaccharides for conjugate vaccines |
| 07/29/2010 | US20100189739 Immunogenic compositions comprising dal/dat double mutant, auxotrophic attenuated strains of Listeria and their methods of use |
| 07/29/2010 | US20100189738 PORIN B (PorB) AS A THERAPEUTIC TARGET FOR PREVENTION AND TREATMENT OF INFECTION BY CHLAMYDIA |
| 07/29/2010 | US20100189737 Meningococcal vaccines including hemoglobin receptor |
| 07/29/2010 | US20100189736 Circovirus sequences associated with piglet weight loss disease (pwd) |
| 07/29/2010 | US20100189735 Circovirus sequences associated with piglet weight loss disease (pwd) |
| 07/29/2010 | US20100189734 Circovirus sequences associated with piglet weight loss disease (pwd) |
| 07/29/2010 | US20100189733 Circovirus sequences associated with piglet weight loss disease (pwd) |
| 07/29/2010 | US20100189732 Circovirus sequences associated with piglet weight loss disease (pwd) |
| 07/29/2010 | US20100189731 Recombinant avian influenza vaccine and uses thereof |
| 07/29/2010 | US20100189730 Vaccines for human papilloma virus and methods for using the same |
| 07/29/2010 | US20100189729 Rna-coded antibody |
| 07/29/2010 | US20100189728 Generation of Antigen Specific T Cells |
| 07/29/2010 | US20100189727 Masking Ligands For Reversible Inhibition Of Multivalent Compounds |
| 07/29/2010 | US20100189726 Lpaat-beta inhibitors and uses thereof |
| 07/29/2010 | US20100189725 P53 modulator and cancer target |
| 07/29/2010 | US20100189724 Method for screening of patient to be administered with pharmaceutical agent comprising anti-cancer antibody as active ingredient |
| 07/29/2010 | US20100189723 Anti-kir antibodies, formulations, and uses thereof |
| 07/29/2010 | US20100189722 Anti cd37 antibodies |
| 07/29/2010 | US20100189721 Antibody formulations |
| 07/29/2010 | US20100189720 Novel card proteins involved in cell death regulation |
| 07/29/2010 | US20100189719 using monoclonal antibody or an Fab fragment capable of binding to mouse Vascular endothelial cell growth factor (VEGF) and human VEGF; cancer, diabetes related diseases, age-induced macular degeneration |
| 07/29/2010 | US20100189718 Molecules with extended half-lives, compositions and uses thereof |
| 07/29/2010 | US20100189717 Plant Recombinant Human CTLA4IG and a Method for Producing the Same |
| 07/29/2010 | US20100189716 Treatment of hodgkins lymphoma |
| 07/29/2010 | US20100189715 Humanized monoclonal antibodies that protect against shiga toxin induced disease |
| 07/29/2010 | US20100189714 Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods |
| 07/29/2010 | US20100189713 Use of Semaphorin 6A for Promoting Myelination and Oligodendrocyte Differentiation |
| 07/29/2010 | US20100189712 Preparation And Use Of Cell-Synthesized Threads |
| 07/29/2010 | US20100189711 Tumor immunity |
| 07/29/2010 | US20100189689 Tetrameric Cytokines with Improved Biological Activity |
| 07/29/2010 | US20100189687 Modulators of pharmacokinetic properties of therapeutics |
| 07/29/2010 | US20100189686 Albumin Fusion Proteins |
| 07/29/2010 | US20100189685 Antiviral Drugs for Treatment or Prevention of Dengue Infection |
| 07/29/2010 | US20100189684 USE OF gp130 ACTIVATORS IN DIABETIC NEUROPATHY |
| 07/29/2010 | US20100189683 Pulsatile Dosing of Gossypol for Treatment of Disease |
| 07/29/2010 | US20100189682 Biologically active proteins having increased In Vivo and/or In Vitro stability |
| 07/29/2010 | US20100189680 Methods of Treating Various Cancers Using Melanoma Differentiating Associated Protein-7 |
| 07/29/2010 | US20100189655 Methods for treating headache |
| 07/29/2010 | US20100189652 Novel diagnostic markers, especially for in vivo imaging, and assays and methods of use thereof |
| 07/29/2010 | US20100189651 Modified antibody compositions, methods of making and using thereof |
| 07/29/2010 | US20100189650 Near-Infrared Responsive Carbon Nanostructures |
| 07/29/2010 | US20100189649 Monoclonal antibodies to activated erbb family members and methods of use |
| 07/29/2010 | US20100189641 Novel Strategies for Improved Cancer Vaccines |
| 07/29/2010 | CA2750581A1 Pta089 protein |
| 07/29/2010 | CA2750533A1 Stabilized fc polypeptides with reduced effector function and methods of use |
| 07/29/2010 | CA2750524A1 Systems and methods to facilitate electronic payments |
| 07/29/2010 | CA2750444A1 Anti-cd 160 monoclonal antibodies and uses thereof |
| 07/29/2010 | CA2750321A1 Stable vaccine compositions and methods of use |
| 07/29/2010 | CA2750098A1 Compositions and methods for induction of antigen-specific tolerance |
| 07/29/2010 | CA2749213A1 Mycoplasma gallisepticum formulation |
| 07/28/2010 | EP2210945A2 Neisseria meningitidis antigens |
| 07/28/2010 | EP2210939A1 Anti-bst2 antibody |
| 07/28/2010 | EP2210903A1 Anti-CD160 monoclonal antibodies and uses thereof |
| 07/28/2010 | EP2210902A1 Recombinant monovalent antibodies |
| 07/28/2010 | EP2210901A1 Antibody capable of specifically binding to a oligomer, and use thereof |
| 07/28/2010 | EP2209810A1 Viral therapeutic |
| 07/28/2010 | EP2209804A1 Monoclonal antibody for app |